Excited to share our new publication: Clinical Characteristics, Management and Outcomes of Non-ICU Candidemia – a subanalysis of the ECMM Candida III multinational European cohort study. 😊
https://t.co/f7TbAnIa6n
@martinhoenigl@SarahSedik@jprattes@CornelyOliver
Clinical characteristics, management and outcomes of non-ICU candidemia: Sub-analysis of the ECMM Candida III multinational European observational cohort study
@eurconfmedmycol@Stella_A_I@SarahSedik@EcmmCandidaIV https://t.co/NZu0u28xUc
🧫 Persistent candidemia: lessons from a European cohort
In 258 patients from 18 countries, 20% had ≥5 days of (+) cultures → higher mortality (50% vs 32%).
Low EQUAL #Candida Scores predicted persistence
💡 Adherence saves lives
🔗 https://t.co/Nx4atkp8i5
⏰Only 70 days left to join the ECMM #CandidaIV study!
🌎 A global, multicenter study on non-albicans Candida infections
🔬 Focus: Resistance, tolerance & clinical outcomes in #candidemia
📅 Enrollment open until September 30, 2025
📥 Register now and be part of it!
Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here: https://t.co/XAsWJjEjO1
@martinhoenigl
@Stella_A_I
@SarahSedik https://t.co/XAsWJjEjO1
ECMM Candida IV Study is still open for participation
Global study on non-albicans candidemia
Requirements:
🔬Clinical data + isolates (no limit per site)
📅Apr 2024-Sep 2025
📦Ship isolates in one batch at study end
💰Case-based reimbursement available
@eurconfmedmycol